NEURON23
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. The company was founded in 2018 and is based in San Francisco, California, United States.
NEURON23
Industry:
Health Care Medical Pharmaceutical
Founded:
2018-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.neuron23.com
Total Employee:
11+
Status:
Active
Total Funding:
213.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Current Advisors List
Current Employees Featured
Founder
Investors List
Surveyor Capital
Surveyor Capital investment in Series C - Neuron23
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series C - Neuron23
Acorn Bioventures
Acorn Bioventures investment in Series C - Neuron23
Westlake Village BioPartners
Westlake Village BioPartners investment in Series C - Neuron23
SoftBank Vision Fund
SoftBank Vision Fund investment in Series C - Neuron23
Perceptive Advisors
Perceptive Advisors investment in Series C - Neuron23
Redmile Group
Redmile Group investment in Series C - Neuron23
HBM Partners
HBM Partners investment in Series C - Neuron23
Kleiner Perkins
Kleiner Perkins investment in Series C - Neuron23
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - Neuron23
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-12 | Neuron23 Appoints Sam Jackson, M.D., MBA, as Chief Medical Officer |
Official Site Inspections
http://www.neuron23.com Semrush global rank: 5.5 M Semrush visits lastest month: 1.55 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Neuron23"
Neuron23
We're a diverse team with proven success in both science and business, driven by one common goal: enhancing and improving the lives of the patients we serve. Compassion is at our core, …See details»
Neuron23
We're a diverse leadership team with proven success in both science and business, driven by one common goal: enhancing and improving the lives of the patients we serve. Nancy is fascinated …See details»
Neuron23
Neuron23 was founded in late 2018 with the goal of changing the way drugs were discovered and developed for neurodegenerative and immunological diseases, by leveraging data science to pinpoint and exploit key disease drivers.See details»
Neuron23 - LinkedIn
Neuron23â„¢ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.See details»
Neuron23 - Crunchbase Company Profile & Funding
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. The company was founded in 2018 and is based in San Francisco, California, United States. A brain-penetrant leucine-rich repeat …See details»
Neuron23 Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Neuron23. Use the PitchBook Platform to explore the full profile.See details»
Neuron23â„¢ Closes $113.5 Million Series A and B Financing led by ...
Dec 16, 2020 · Neuron23â„¢ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.See details»
Neuron23 Announces Usage of Roche’s Digital Biomarker and …
Nov 19, 2024 · Neuron23 is using a Roche-developed digital biomarker as the primary endpoint in the Phase 2 NEULARK trial of NEU-411 in early Parkinson’s disease.See details»
Neuron23's CEO Nancy Stagliano: Bringing AI to Life
Serial entrepreneur and CEO Nancy Stagliano talks about company building and using machine learning to develop individualized therapies. Precision medicine is exactly what it sounds like: the right therapy for the right patient at the right time.See details»
Neuron23â„¢ Closes $113.5 Million Series A and B Financing
Dec 16, 2020 · Neuron23â„¢ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.See details»
Neuron23, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Neuron23 is a biotechnology corporation headquartered in South San Francisco, California. The company specializes in creating tailored medications for neurological and immunological …See details»
Precision medicine for a neurological disease that can affect
Neuron23 is a venture-backed biotechnology clinical-stage startup in South San Francisco that uses advanced techniques in artificial intelligence (AI) and data science to create precision …See details»
Neuron23 Emerges from Stealth with $113.5 Million Financing
Dec 18, 2020 · Neuron23 Inc. founded in 2018 through a partnership with German biotechnology company, Origenis GmbH, has recently come out of stealth mode.See details»
Adam Knight - Founder and CBO at Neuron23 - The Org
In September 2017, Adam joined Kleiner Perkins to create a biotech company with Beth Seidenberg, which became Neuron23, a firm committed to leveraging recent innovations in …See details»
Neuron23: Nancy Stagliano, CEO - by Dylan Neel - Biomarker
Jul 21, 2022 · Neuron23 is taking a precision approach to treating genetically defined neurodegenerative and systemic inflammatory disorders. The company uses machine learning …See details»
Neuron23 and QIAGEN Announce Collaboration to Develop the …
Sep 14, 2022 · Collaboration combines leading expertise of Neuron23 in drug discovery, data science, and machine learning with QIAGEN's long-standing experience in companion …See details»
Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial …
Feb 7, 2023 · NEU-723 is a highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor. First-of-its-kind companion diagnostic paired with NEU-723 will enable selection of …See details»
Neuron23 to Launch Phase II Trial in LRRK2-Driven Parkinson's in …
Nov 21, 2024 · Neuron23 has also partnered with Sano Genetics, a biotech company that offers genetic testing and recruits patients for clinical trials, to offer saliva test kits to identify patients …See details»
Neuron23 Closes $100 Million Series C Financing Round, …
Mar 30, 2022 · Neuron23â„¢ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.See details»
Neuron23 to test Parkinson's with Roche app - IoT M2M Council
4 days ago · Neuron23 is incorporating Roche digital biomarkers in a global trial of NEU-411, a selective inhibitor of LRRK2, in early-stage Parkinson’s disease (PD). Neuron23 is a clinical …See details»